Dr. Jorge Cortes discusses new data on bosutinib, a new tyrosine kinase inhibitor for CML.
FDA Grants Breakthrough Therapy Status to Ziftomenib in R/R NPM1+ AML
Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Olutasidenib Yields Enduring Remissions in Previously Treated IDH1+ AML
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
Novel CDK9 Inhibitor Yields Responses in Relapsed/Refractory AML
Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.
Revumenib Receives FDA Priority Review in R/R KMT2Ar Acute Leukemia
Data from the phase 2 AUGMENT-101 trial support the biologics license application for revumenib in patients with relapsed/refractory KMT2A-rearranged acute leukemia.
